Denmark’s COPENHAGEN, July 18, 2023 CathVision, a provider of cutting-edge electrophysiology solutions to support clinical judgment in the EP lab, recently announced closing a USD 9 million investment round.

The funding will support the development of artificial intelligence-powered analytic modules to give electrophysiologists unprecedented levels of automated analysis during cardiac ablation procedures and advance commercial operations, driving the adoption of the ECGeniusTM System, the company’s innovative EP recording technology.1 This involves growing the company’s sales force and presence in the United States and advancing the CARDIALYTICSTM analytics-powered by artificial intelligence. With its most recent round of fundraising, CathVision now has approximately USD 30 million in total funding.

Despite trying times in the financial markets, Mads Matthiesen, CEO of CathVision, said, “We are achieving critical milestones that validate the need for our technology, revenue generation through successful commercialization, and our commitment to ongoing R&D. In order to position CathVision to have a substantial impact on how we help physicians treat cardiac arrhythmias more effectively across the United States, this funding round will support the acceleration of commercial adoption through 2024.

A specialized hardware amplifier that can record high-fidelity, low-noise cardiac electrograms is part of the ECGenius System. In order to assist electrophysiologists in bettering the overall diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation (AF), which raises the risk of stroke and heart failure, the technology represents a critical advancement in the quality of cardiac signal acquisition, the accuracy of electrogram interpretation, and the advancement of therapy support. The FDA granted 510(k) clearance for the ECGenius System in May 2022, and it is now accessible.

Since the announcement of its most recent investment round in August 2022, CathVision has accomplished several significant milestones, including:

  • Beginning of a clinical trial with NYU Health Langone to test the Signal ComplexityTM algorithm3
  • Hospitals using the ECGenius System in more locations
  • the conclusion of three clinical trials with successful primary outcomes
  • An enhanced portfolio of intellectual property (IP)
  • It has boosted industry awareness by presenting seven scientific abstracts at the 2023 Heart Rhythm Society (HRS) conference that uses CathVision technology.

A medical technology business called CathVision creates electrophysiology solutions based on ECGenius equipment, cutting-edge EP recording equipment, and an AI algorithm platform. Activision is redefining the necessity of excellent cardiac electrical signals to diagnose, characterize, and treat the most prevalent heart rhythm abnormalities. This enables doctors to make more informed clinical decisions in the EP lab. With its headquarters in Denmark and a U.S. branch in Minnesota, CathVision was established in 2013.

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleThunes receives backing from Visa, EDBI, and Endeavour Catalyst to increase Series C funding to USD 72 million
Next articleBangalore-based fraud detection startup Bureau raises USD 16.5 million in Series A funding round
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.


Please enter your comment!
Please enter your name here